A Phase 1 interventional study of MK-6194 in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-21.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this study is to learn what happens to MK-6194 in a healthy person's body when different injection sites are used. Researchers will compare what happens to MK-6194 in a healthy person's body when it is injected into the abdomen and when it is injected into the thigh. Researchers think that the average amount of MK-6194 in a person's body over time will be similar when injected into the thigh or abdomen. They also want to learn if it is safe to inject MK-6194 into the abdomen and thigh, and if people tolerate it.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The key inclusion criteria include but are not limited to the following:
Exclusion Criteria:
The key exclusion criteria include but are not limited to the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single dose of MK-6194 injected into the abdomen.
Biological: MK-6194
Participants will receive a single dose of MK-6194 injected into the thigh.
Biological: MK-6194
single injected dose
Also known as: PT101
Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of MK-6194
Blood samples will be collected to determine the AUC0-Last of MK-6194.
Time frame: At designated timepoints (up to approximately 4 weeks postdose)
Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of MK-6194
Blood samples will be collected to determine the AUC0-Inf of MK-6194.
Time frame: At designated timepoints (up to approximately 4 weeks postdose)
Maximum Plasma Concentration (Cmax) of MK-6194
Blood samples will be collected to determine the Cmax of MK-6194.
Time frame: At designated timepoints (up to approximately 4 weeks postdose)
Time to Maximum Plasma Concentration (Tmax) of MK-6194
Blood samples will be collected to determine the Tmax of MK-6194.
Time frame: At designated timepoints (up to approximately 4 weeks postdose)
Apparent Clearance (CL/F) of MK-6194
Blood samples will be collected to determine the CL/F of MK-6194.
Time frame: At designated timepoints (up to approximately 4 weeks postdose)
Apparent Terminal Half-life (t1/2) of MK-6194
Blood samples will be collected to determine the t1/2 of MK-6194.
Time frame: At designated timepoints (up to approximately 4 weeks postdose)
Apparent Volume of Distribution (Vz/F) of MK-6194
Blood samples will be collected to determine the Vz/F of MK-6194.
Time frame: At designated timepoints (up to approximately 4 weeks postdose)
Number of Participants Who Experience an Adverse Event
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.
Time frame: Up to approximately 12 weeks
Number of Participants Who Discontinue Study Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study due to an AE will be reported.
Time frame: Up to approximately 12 weeks
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Mar 2023 to primary completion in Jul 2023, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MK-6194